FOLFOX in Combination with Binimetinib as 2nd Line Therapy for Patients with Advanced Biliary Tract Cancers with MAPK Pathway Alterations: A ComboMATCH Treatment Trial
(See required screening study ECOG-ACRIN EAY191)
EAY191-A6 is temporarily closed to accrual, effective March 13, 2025 4:30 pm ET.